Drug Profile
APN 401
Alternative Names: APN-401; siRNA-transfected PBMC APN401; siRNA-transfected peripheral blood mononuclear cells - ApeironLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Apeiron Biologics
- Developer Apeiron Biologics; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (USA)
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Sep 2023 InvIOs plans a phase II trial for Solid tumours (Late stage disease, Metastatic disease, Second line therapy or greater) in Austria
- 18 Apr 2023 Efficacy data from a phase-I trial in Solid tumours released by invIOs
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)